Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

AEON

AEON Biopharma Inc.

Last Close
May 23 • 04:00PM ET
1.69
Dollar change
-0.30
Percentage change
-15.08 		%
Scroll to Statements
Index- P/E- EPS (ttm)-4.14 Insider Own69.30% Shs Outstand37.16M Perf Week12.67%
Market Cap66.11M Forward P/E- EPS next Y-0.87 Insider Trans0.00% Shs Float12.01M Perf Month-57.86%
Income-141.82M PEG- EPS next Q-0.19 Inst Own15.24% Short Float1.60% Perf Quarter-85.18%
Sales0.00M P/S- EPS this Y-1909.52% Inst Trans4.33% Short Ratio1.90 Perf Half Y-64.04%
Book/sh-5.20 P/B- EPS next Y77.11% ROA-1150.77% Short Interest0.19M Perf Year-83.68%
Cash/sh0.04 P/C42.38 EPS next 5Y- ROE-27.38% 52W Range1.38 - 17.17 Perf YTD-76.53%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-90.16% Beta0.51
Dividend TTM- Quick Ratio0.16 Sales past 5Y0.00% Gross Margin- 52W Low22.46% ATR (14)0.51
Dividend Ex-Date- Current Ratio0.16 EPS Y/Y TTM-4975.41% Oper. Margin0.00% RSI (14)30.35 Volatility13.27% 15.83%
Employees10 Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price6.00
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q-16223.20% Payout- Rel Volume0.90 Prev Close1.99
Sales Surprise- EPS Surprise-922.58% Sales Q/Q- EarningsMay 14 AMC Avg Volume101.01K Price1.69
SMA20-28.74% SMA50-74.31% SMA200-74.84% Trades Volume90,843 Change-15.08%
Date Action Analyst Rating Change Price Target Change
Aug-18-23Initiated H.C. Wainwright Buy $18
May-14-24 04:05PM
AEON Biopharma Reports First Quarter 2024 Financial Results
(GlobeNewswire)
May-09-24 09:35AM
AEON Biopharma, Inc. (AEON) Loses -79.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
(Zacks) -6.21%
08:00AM
AEON Biopharma Provides Update on Development Pipeline
(GlobeNewswire)
May-03-24 04:08PM
US Equity Markets Close Higher Friday Following Weak Jobs Report
(MT Newswires) -49.40%
03:55PM
Sector Update: Health Care Stocks Mixed Late Afternoon
(MT Newswires)
02:37PM Loading…
02:37PM
Top Midday Decliners
(MT Newswires)
09:05AM
Sector Update: Health Care Stocks Mixed Pre-Bell Friday
(MT Newswires)
08:31AM
AEON Biopharma Shares Slump Pre-Bell After Failed Chronic Migraine Phase 2 Trial
(MT Newswires)
07:00AM
AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine
(GlobeNewswire)
Mar-30-24 10:53PM
CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants
(GlobeNewswire)
Mar-29-24 04:15PM
AEON Biopharma Announces Redemption of Public Warrants
(GlobeNewswire)
03:45PM
AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results
(GlobeNewswire)
Mar-19-24 04:30PM
AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine
(GlobeNewswire) -11.60%
04:29PM
AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements
(GlobeNewswire)
Jan-18-24 04:05PM
AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference
(GlobeNewswire)
08:00AM Loading…
Dec-12-23 08:00AM
AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine
(GlobeNewswire)
Nov-15-23 04:49AM
AEON Biopharma Inc Reports Q3 2023 Financial Results Amid Clinical Advancements
(GuruFocus.com) +7.61%
Nov-13-23 08:15AM
AEON Biopharma Reports Third Quarter 2023 Financial Results
(GlobeNewswire)
Oct-19-23 04:05PM
AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine
(GlobeNewswire)
Aug-29-23 08:00AM
AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®
(GlobeNewswire)
Aug-24-23 08:00AM
AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache
(GlobeNewswire) +14.91%
Aug-16-23 07:00AM
Strathspey Crown Holdings Group, LLC Provides Clarifying Statement Regarding Form 4 Filing with SEC for Holdings in AEON Biopharma
(GlobeNewswire) +7.06%
Jul-24-23 07:00AM
AEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update
(GlobeNewswire) -15.13%
AEON Biopharma, Inc. is a biopharmaceutical company. It engages in the business of developing proprietary botulinum toxin complex, ABP-450 injection, for debilitating medical conditions. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Irvine, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Strathspey Crown Holdings Grou10% OwnerAug 11 '23Sale10.007,380,39473,803,9402,031,773Aug 14 04:10 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.